Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)

被引：36

作者：

Rosenberg, J. E. ^{[1
]}

Milowsky, M. ^{[2
]}

Ramamurthy, C. ^{[3
]}

Mar, N. ^{[4
]}

Mckay, R. R. ^{[5
]}

Friedlander, T. ^{[6
]}

Ferrario, C. ^{[7
]}

Bracarda, S. ^{[8
]}

George, S. ^{[9
]}

Moon, H. ^{[10
]}

Geynisman, D. ^{[11
]}

Petrylak, D. P. ^{[12
]}

Borchiellini, D. ^{[13
]}

Burgess, E. F. ^{[14
]}

Rey, J. P. Maroto ^{[15
]}

Carret, A-S. ^{[16
]}

Yu, Y. ^{[17
]}

Guseva, M. V. ^{[18
]}

Moreno, B. Homet ^{[19
]}

O'Donnell, P. H. ^{[20
]}

机构：

[1] MSKCC Mem Sloan Kettering Canc Ctr, Med Dept, New York, NY USA

[2] Univ North Carolina Chapel Hill, Med Dept, Chapel Hill, NC USA

[3] Univ Texas Hlth Sci Ctr San Antonio, Mays Canc Ctr, Hematol, San Antonio, TX USA

[4] Univ Calif Irvine, UCI Hlth, Hematol Oncol, Orange, CA USA

[5] Univ Calif San Diego, Med Oncol, La Jolla, CA USA

[6] UCSF Univ Calif San Francisco, Oncol, San Francisco, CA USA

[7] Jewish Gen Hosp, Oncol, Montreal, PQ, Canada

[8] Azienda Osped Santa Maria, Med Translat Oncol Unit, Terni, Italy

[9] Roswell Pk Comprehens Canc Ctr, Med Dept, Buffalo, NY USA

[10] Kaiser Permanente Riverside Med Ctr, Oncol Dept, Riverside, CA USA

[11] Fox Chase Canc Ctr, Med Oncol Dept, Main Campus, Philadelphia, PA USA

[12] Yale Univ, Med Oncol Dept, Sch Med, New Heaven, CT USA

[13] Ctr Antoine Lacassagne, Oncol, Nice, France

[14] Levine Canc Inst, Dept Med Oncol, Charlotte, NC USA

[15] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

[16] Seagen Inc, Clin Dev, Bothell, WA USA

[17] Seagen Inc, Biostat, Bothell, WA USA

[18] Astellas Pharma USA, Oncol, Global Medica Affairs, Northbrook, IL USA

[19] Merck & Co Inc, Clin Res, Rahway, NJ USA

[20] Univ Chicago, Hematol & Oncol, Chicago, IL USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.08.079

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA73

引用

页码：S1441 / S1441

页数：1

共 50 条

[41] Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer
van der Heijden, M. S.
Gupta, S.
Galsky, M. D.
Derleth, C.
Steinberg, J.
Kataria, R.
Powles, T. B.
ANNALS OF ONCOLOGY, 2020, 31 : S605 - S606
[42] EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors
O'Donnell, P.
Galsky, M. D.
Rosenberg, J. E.
Petrylak, D. P.
Balar, A. V.
McGregor, B. A.
Heath, E.
Yu, E. Y.
Quinn, D. I.
Hahn, N. M.
Campbell, M.
Liang, S-Y.
Steinberg, J.
Loriot, Y.
ANNALS OF ONCOLOGY, 2020, 31 : S579 - S580
[43] EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy
Rosenberg, J. E.
Balar, A.
O'Donnell, P. H.
Heath, E. I.
Hahn, N. M.
Cavazos, N. M.
Melhem-Bertrandt, A.
Petrylak, D. P.
ANNALS OF ONCOLOGY, 2018, 29
[44] Study EV-302: A two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress).
Van der Heijden, Michiel Simon
Gupta, Shilpa
Galsky, Matt D.
Derleth, Christina Louise
Lee, Sue
Kataria, Ritesh S.
Powles, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[45] Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)
Rosenberg, J. E.
Galsky, M. D.
Balar, A. V.
Loriot, Y.
Necchi, A.
Hoffman-Censits, J.
Srinivas, S.
Drakaki, A.
Javery, A.
Nelson, B.
Huang, H. X.
Shen, X.
Van der Heijden, M. S.
ANNALS OF ONCOLOGY, 2021, 32 : S711 - S712
[46] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Balar, Arjun V.
Castellano, Daniel
O'Donnell, Peter H.
Grivas, Petros
Vuky, Jacqueline
Powles, Thomas
Plimack, Elizabeth R.
Hahn, Noah M.
de Wit, Ronald
Pang, Lei
Savage, Mary J.
Perini, Rodolfo F.
Keefe, Stephen M.
Bajorin, Dean
Bellmunt, Joaquim
LANCET ONCOLOGY, 2017, 18 (11): : 1483 - 1492
[47] Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study.
Rosenberg, Jonathan E.
Gajate, Pablo
Morales-Barrera, Rafael
Lee, Jae-Lyun
Necchi, Andrea
Penel, Nicolas
Zagonel, Vittorina
Sierecki, Mitchell Robert
Bao, Weichao
Zhou, Yinghui
Ellinghaus, Peter
Sweis, Randy F.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[48] Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
Vuky, Jacqueline
Balar, Arjun V.
Castellano, Daniel
O'Donnell, Peter H.
Grivas, Petros
Bellmunt, Joaquim
Powles, Thomas
Bajorin, Dean
Hahn, Noah M.
Savage, Mary J.
Fang, Xiao
Godwin, James Luke
Frenkl, Tara L.
Moreno, Blanca Homet
de Wit, Ronald
Plimack, Elizabeth R.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23) : 2658 - +
[49] Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression
Rosenberg, J.
Necchi, A.
Sweis, R. F.
Nakajima, K.
Lu, C.
Nogai, H.
ANNALS OF ONCOLOGY, 2018, 29 : 329 - 329
[50] Epidemiology, treatment (tx) patterns, and clinical outcomes of patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) in Taiwan: A retrospective cohort study
Wu, C-T.
Young, L.
Lee, A.
Ku, M-Y.
Hsieh, Y-C.
Lin, H-W.
Lin, K-L.
Chou, K-P.
Kearney, M.
Chien, L-N.
ANNALS OF ONCOLOGY, 2024, 35 : S1511 - S1511

← 1 2 3 4 5 →